Immunome (NASDAQ:IMNM) Insider Robert Lechleider Sells 55,000 Shares

by · The Markets Daily

Immunome, Inc. (NASDAQ:IMNM – Get Free Report) insider Robert Lechleider sold 55,000 shares of the stock in a transaction dated Thursday, July 2nd. The stock was sold at an average price of $22.62, for a total transaction of $1,244,100.00. Following the transaction, the insider owned 15,805 shares in the company, valued at approximately $357,509.10. The trade was a 77.68% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Robert Lechleider also recently made the following trade(s):

  • On Thursday, June 25th, Robert Lechleider sold 55,000 shares of Immunome stock. The stock was sold at an average price of $19.85, for a total transaction of $1,091,750.00.

Immunome Stock Performance

Immunome stock opened at $24.39 on Wednesday. Immunome, Inc. has a 1 year low of $7.96 and a 1 year high of $27.65. The firm has a 50 day moving average price of $20.99 and a 200 day moving average price of $21.83. The company has a market cap of $2.76 billion, a price-to-earnings ratio of -10.25 and a beta of 2.07.

Immunome (NASDAQ:IMNM – Get Free Report) last posted its quarterly earnings results on Tuesday, May 12th. The company reported ($0.48) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.60) by $0.12. Sell-side analysts predict that Immunome, Inc. will post -2.06 EPS for the current year.

Wall Street Analyst Weigh In

IMNM has been the topic of a number of research analyst reports. Barclays assumed coverage on Immunome in a report on Thursday, May 28th. They issued an “overweight” rating and a $36.00 target price on the stock. Wall Street Zen downgraded Immunome from a “hold” rating to a “sell” rating in a report on Saturday, May 30th. Leerink Partners reduced their price objective on Immunome from $37.00 to $33.00 and set an “outperform” rating on the stock in a research note on Friday, May 15th. HC Wainwright reiterated a “buy” rating and set a $40.00 target price on shares of Immunome in a report on Wednesday, May 13th. Finally, Truist Financial increased their target price on shares of Immunome from $36.00 to $37.00 and gave the stock a “buy” rating in a research report on Thursday, May 28th. Twelve analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Immunome has an average rating of “Moderate Buy” and an average price target of $33.17.

Read Our Latest Analysis on Immunome

Institutional Trading of Immunome

Several large investors have recently added to or reduced their stakes in IMNM. Creative Planning raised its position in Immunome by 4.0% in the third quarter. Creative Planning now owns 18,664 shares of the company’s stock valued at $219,000 after purchasing an additional 710 shares during the period. Russell Investments Group Ltd. grew its stake in shares of Immunome by 14.4% in the fourth quarter. Russell Investments Group Ltd. now owns 7,417 shares of the company’s stock valued at $159,000 after buying an additional 935 shares in the last quarter. California State Teachers Retirement System grew its stake in shares of Immunome by 1.8% in the fourth quarter. California State Teachers Retirement System now owns 67,012 shares of the company’s stock valued at $1,439,000 after buying an additional 1,167 shares in the last quarter. Assetmark Inc. raised its holdings in shares of Immunome by 46.6% during the 1st quarter. Assetmark Inc. now owns 4,535 shares of the company’s stock valued at $99,000 after buying an additional 1,442 shares during the period. Finally, Virtus Investment Advisers LLC raised its holdings in shares of Immunome by 16.9% during the 4th quarter. Virtus Investment Advisers LLC now owns 13,593 shares of the company’s stock valued at $292,000 after buying an additional 1,970 shares during the period. 44.58% of the stock is currently owned by institutional investors and hedge funds.

About Immunome

(Get Free Report)

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.

See Also